Fundz

Qi Biodesign raised $75M in its Series A funding round led by Beijing Medical and Health Care Industry Investment Fund to enhance R&D capabilities and advance its SEEDIT platform.

PRIVATEDec 09, 2024

Amount Raised

$75 Million

Round Type

Series A

BeijingBiotechnology

Investors

CasstarShang CapitalCssd CapitalGaorong VenturesSource Code CapitalApricot CapitalCd CapitalMingzhe CapitalBeijing Changping Technology Innodevelop GroupBeijing Medical And Health Care Industry Investment Fund (Limited Partnership)

Description

Qi Biodesign announced the completion of its Series A funding round, raising a total of $75 million. This funding will improve its R&D capabilities, support product development, and commercialize its cutting-edge genome editing technologies.

Quick answer

Qi Biodesign raised $75 Million in a Series A round, dated December 9, 2024. Investors: Casstar, Shang Capital, Cssd Capital, Gaorong Ventures, Source Code Capital, Apricot Capital, Cd Capital and Mingzhe Capital. Qi Biodesign is based in Beijing, Beijing, China.

How much did Qi Biodesign raise?
Qi Biodesign raised $75 Million in a Series A round on December 9, 2024.
Who invested in Qi Biodesign?
Casstar, Shang Capital, Cssd Capital, Gaorong Ventures, Source Code Capital, Apricot Capital, Cd Capital and Mingzhe Capital are named as investors in this round.
What does Qi Biodesign do?
Qi Biodesign is a biotechnology company focused on developing next-generation genome editing technologies.
Where is Qi Biodesign based and how big is it?
Qi Biodesign is based in Beijing, Beijing, China.
Who are the decision-makers at Qi Biodesign?
Fundz holds 1 contact at Qi Biodesign. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Qi Biodesign that raised within 45 days of this round, from Fundz verified event records.

  • MyndTec raised $100K (Pre-Seed) on January 23, 2025.
  • MED-X raised $428K on January 23, 2025.
  • Sycai Medical raised $3.1M (Seed) on January 23, 2025.
  • SVASTEK raised $231K (Seed) on January 23, 2025.
  • Nuclein raised $750K (Seed) on January 23, 2025.
  • Resynergi raised $18M on January 23, 2025.

Who to call at Qi Biodesign, and when

A new round usually means Qi Biodesign is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Qi Biodesign raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Qi Biodesign, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Qi Biodesign. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Qi Biodesign

Location

Beijing, Beijing, China

About

Qi Biodesign is a biotechnology company focused on developing next-generation genome editing technologies. Founded in 2021 by leading genome editing scientists, the company has established its proprietary SEEDIT research platform, which features advanced genome editing tools. Their innovations aim to enhance crop breeding and address global challenges in agriculture and synthetic biology. Qi Biodesign has already achieved significant milestones in product development, including receiving biosafety certifications for gene-edited plants.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Qi Biodesign raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for Qi Biodesign's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Qi Biodesign raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.